Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYC008
MIFTS: 59

Myocarditis

Categories: Cardiovascular diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Myocarditis

About this section

MalaCards integrated aliases for Myocarditis:

Name: Myocarditis 12 74 52 54 6 15 17 71
Myocardial Inflammation 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:820
ICD9CM 34 429.0
NCIt 49 C34831
SNOMED-CT 67 50920009
ICD10 32 I41 I41.8 I51.4
UMLS 71 C0027059
Sources

Summaries for Myocarditis

About this section
NIH Rare Diseases : 52 Myocarditis is a condition that is characterized by inflammation of the heart muscle (myocardium). Some affected people have no noticeable symptoms of the condition. When present, signs and symptoms may include chest pain, abnormal heartbeat, shortness of breath, fatigue, signs of infection (i.e. fever, headache, sore throat, diarrhea), and leg swelling. Myocarditis can be caused by a variety of factors including infections (viral, bacterial, parasitic, and fungal), allergic reactions to certain medications, and exposure to certain chemicals. It can also be associated with other inflammatory conditions such as lupus , Wegener's granulomatosis , giant cell arteritis and Takayasu's arteritis . Most cases occur sporadically in people with no family history of the condition. Treatment aims to address the underlying cause of the condition. Medications and rarely, a heart transplant may be needed if the heart muscle becomes weak.

MalaCards based summary : Myocarditis, also known as myocardial inflammation, is related to giant cell myocarditis and rheumatic myocarditis. An important gene associated with Myocarditis is CXADR (CXADR Ig-Like Cell Adhesion Molecule), and among its related pathways/superpathways are Viral myocarditis and Innate Immune System. The drugs Oseltamivir and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include heart, t cells and endothelial, and related phenotypes are cardiovascular system and cellular

Disease Ontology : 12 An extrinsic cardiomyopathy that is characterized as an inflammation of the heart muscle.

Wikipedia : 74 Myocarditis, also known as inflammatory cardiomyopathy, is inflammation of the heart muscle. Symptoms... more...

Sources

Related Diseases for Myocarditis

About this section

Diseases in the Myocarditis family:

Acute Myocarditis Autoimmune Myocarditis
Infectious Myocarditis

Diseases related to Myocarditis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 943)
# Related Disease Score Top Affiliating Genes
1 giant cell myocarditis 35.1 MB HLA-B
2 rheumatic myocarditis 34.6 TNNI3 MB
3 toxic myocarditis 34.5 TNNI3 NPPB
4 acute myocarditis 34.4 TNNI3 TNF NPPB CD86 CD40
5 drug reaction with eosinophilia and systemic symptoms 33.4 TNF HLA-B
6 chagas disease 33.0 TNF NPPB NOS2 IL6
7 dilated cardiomyopathy 31.8 TNNI3 TNF NPPB NOS2 MYH6 MB
8 atrial standstill 1 31.8 TNNI3 NPPB MYH6 DSP DMD
9 lupus erythematosus 31.7 TNF HLA-DQB1 CD86 CD40LG CD40
10 congestive heart failure 31.7 TNNI3 TNF NPPB MYH6 IL6
11 sarcoidosis 1 31.7 TNF ICAM1 HLA-DQB1 CD86 CD40LG
12 exanthem 31.7 TNF IL6 CD40LG
13 myositis 31.6 TNF MB IL6 HLA-B DMD
14 cardiac sarcoidosis 31.6 TNF HLA-DQB1 DSP
15 chickenpox 31.6 TNF IL6 CD40LG
16 endocarditis 31.6 TNNI3 TNF IL6
17 autoimmune disease 31.5 TNF IL6 HLA-DQB1 HLA-B CD86 CD55
18 pericarditis 31.5 TNNI3 TNF NPPB IL6 CD40LG
19 cardiac arrest 31.5 NPPB MYH6 ICAM1 DSP
20 mumps 31.5 TNF IL6 HLA-DQB1 CD40LG
21 pericardial effusion 31.5 TNNI3 NPPB IL6 CD40LG
22 typhoid fever 31.4 TNF IL6 HLA-DQB1 CD40LG
23 poliomyelitis 31.4 TNF ICAM1 CD40LG
24 vasculitis 31.4 TNF ITGB2 IL6 ICAM1 HLA-B CD40LG
25 myasthenia gravis 31.4 TNF HLA-DQB1 HLA-B CD86 CD55 CD40LG
26 encephalitis 31.4 TNF NOS2 IL6 CD40LG
27 meningoencephalitis 31.4 TNF IL6 CD40LG
28 chlamydia 31.3 TNF NOS2 IL6 CD40LG
29 q fever 31.3 TNF IL6 CD40LG
30 pharyngitis 31.3 TNF IL6 CD40LG
31 dengue disease 31.2 TNF ICAM1 CD40LG
32 pneumonia 31.2 TNF MB IL6 ICAM1 CD40LG
33 kawasaki disease 31.2 TNF NPPB IL6 CD40LG CD40
34 leptospirosis 31.2 TNF IL6 ICAM1 CD40LG
35 arrhythmogenic right ventricular cardiomyopathy 31.2 NPPB MYH6 DSP DMD DAG1
36 chlamydia pneumonia 31.2 TNF IL6 CD40LG
37 lyme disease 31.2 TNF IL6 HLA-DQB1 CD40LG
38 toxoplasmosis 31.2 TNF NOS2 IL6 HLA-DQB1 CD40LG CD40
39 guillain-barre syndrome 31.2 TNF HLA-DQB1 CD40LG
40 respiratory failure 31.2 TNF NPPB IL6 DMD CD40LG
41 cytomegalovirus infection 31.1 TNF IL6 HLA-B
42 mixed connective tissue disease 31.1 TNF IL6 CD40LG
43 toxic shock syndrome 31.1 TNF NOS2 IL6 CD86 CD40LG CD40
44 proteasome-associated autoinflammatory syndrome 1 31.1 TNF NOS2 IL6 ICAM1
45 bronchopneumonia 31.1 TNF IL6 CD40LG
46 severe acute respiratory syndrome 31.1 TNF IL6 CD40LG
47 brucellosis 31.1 TNF IL6 CD86 CD40LG
48 acute myocardial infarction 31.1 TNNI3 TNF NPPB MB IL6
49 acquired immunodeficiency syndrome 31.1 TNF NOS2 IL6 ICAM1 HLA-B CD40LG
50 rubella 31.1 TNF IL6 HLA-DQB1 HLA-B CD40LG

Comorbidity relations with Myocarditis via Phenotypic Disease Network (PDN):


Acute Cystitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Mitral Valve Disease

Graphical network of the top 20 diseases related to Myocarditis:



Diseases related to Myocarditis
Sources

Symptoms & Phenotypes for Myocarditis

About this section

MGI Mouse Phenotypes related to Myocarditis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 CD40LG CXADR DAG1 DMD DSP HLA-DQB1
2 cellular MP:0005384 10.32 CD40LG CD86 CXADR DAG1 DMD DSP
3 homeostasis/metabolism MP:0005376 10.24 CD40 CD40LG CD55 CD86 CXADR DAG1
4 hematopoietic system MP:0005397 10.22 CD40 CD40LG CD55 CD86 CXADR DMD
5 endocrine/exocrine gland MP:0005379 10.13 CD40 CD40LG CD86 CXADR DMD HLA-DQB1
6 immune system MP:0005387 10.13 CD40 CD40LG CD55 CD86 CXADR DMD
7 mortality/aging MP:0010768 10.13 CD40LG CD55 CXADR DAG1 DMD DSP
8 digestive/alimentary MP:0005381 10.06 CXADR DMD DSP HLA-DQB1 ICAM1 IL6
9 muscle MP:0005369 10 CD55 CD86 CXADR DAG1 DMD DSP
10 nervous system MP:0003631 9.73 CD40 CD40LG CD86 DAG1 DMD DSP
11 respiratory system MP:0005388 9.28 CXADR DMD HLA-DQB1 IL6 MB MYH6
Sources

Drugs & Therapeutics for Myocarditis

About this section

Drugs for Myocarditis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Adalimumab Approved Phase 4 331731-18-1 16219006
3
Abatacept Approved Phase 4 332348-12-6 10237
4 Immunosuppressive Agents Phase 4
5 Immunologic Factors Phase 4
6 Immunoglobulins Phase 4
7 Antibodies Phase 4
8 Immunoglobulins, Intravenous Phase 4
9 Rho(D) Immune Globulin Phase 4
10 gamma-Globulins Phase 4
11 Vaccines Phase 4
12 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
13 Sodium-Glucose Transporter 2 Inhibitors Phase 4
14 Hypoglycemic Agents Phase 4
15
Ramipril Approved Phase 3 87333-19-5 5362129
16
Bisoprolol Approved Phase 3 66722-44-9 2405
17
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
18
Captopril Approved Phase 3 62571-86-2 44093
19
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
20
Angiotensin II Approved, Investigational Phase 3 4474-91-3, 11128-99-7, 68521-88-0 172198
21
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
22 Hematinics Phase 2, Phase 3
23 Ferrosoferric Oxide Phase 2, Phase 3
24 Parenteral Nutrition Solutions Phase 2, Phase 3
25 Neurotransmitter Agents Phase 3
26 Protective Agents Phase 3
27 Adrenergic beta-Antagonists Phase 2, Phase 3
28 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
29 Adrenergic beta-1 Receptor Antagonists Phase 3
30 Adrenergic Antagonists Phase 3
31 Angiotensin-Converting Enzyme Inhibitors Phase 3
32 Sympatholytics Phase 3
33 Adrenergic Agents Phase 3
34
protease inhibitors Phase 3
35 HIV Protease Inhibitors Phase 3
36 Antioxidants Phase 3
37 Trace Elements Phase 3
38 Sodium Selenite Phase 3
39 Nutrients Phase 3
40 Micronutrients Phase 3
41 Anti-Inflammatory Agents Phase 2, Phase 3
42 Antiviral Agents Phase 2, Phase 3
43 Analgesics, Non-Narcotic Phase 2, Phase 3
44 Cyclooxygenase Inhibitors Phase 2, Phase 3
45 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
46 Fibrinolytic Agents Phase 2, Phase 3
47 Platelet Aggregation Inhibitors Phase 2, Phase 3
48 Antipyretics Phase 2, Phase 3
49 Antihypertensive Agents Phase 3
50 Angiotensin II Type 1 Receptor Blockers Phase 3

Interventional clinical trials:

(show top 50) (show all 181)
# Name Status NCT ID Phase Drugs
1 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
2 Effects of Abatacept on Myocarditis in Rheumatoid Arthritis Recruiting NCT03619876 Phase 4 Abatacept;Adalimumab
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 Effects of SGLT-2 Inhibition With Dapagliflozin on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI With T1- and T2-mapping in Patients With Type-2 Diabetes Recruiting NCT03782259 Phase 4 dapagliflozin
5 RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATHY IMMUNOSUPPRESSION TRIAL) Unknown status NCT01877746 Phase 3 Combination of prednisone and azathioprine;Combination of prednisone and azathioprine
6 Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection Unknown status NCT02787382 Phase 3
7 DEtection of Cellular Inflammation With FERumoxytol in the HEART Completed NCT02319278 Phase 2, Phase 3 Ferumoxytol
8 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
9 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
10 Anakinra Versus Placebo Double Blind Randomized Controlled Trial for the Treatment of Acute MyocarditIS Recruiting NCT03018834 Phase 2, Phase 3 ANAKINRA 100 mg/daily subcutaneously;Placebo
11 Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial Recruiting NCT02236806 Phase 3 Bisoprolol;Ramipril;Placebo
12 Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
13 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
14 Protective Effect of Aspirin on COVID-19 Patients Enrolling by invitation NCT04365309 Phase 2, Phase 3 Aspirin 100mg
15 PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction Not yet recruiting NCT04128891 Phase 3 Sacubitril-Valsartan
16 Application of Sildenafil in Patients With Documented Coronary Vasospasm to Explore the Pathophysiology of Coronary Vasospasm and the Therapeutic Effect of Sildenafil in Patients Suffering From Coronary Vasospasm Withdrawn NCT00454714 Phase 3 single dose Sildenafil;Single dose placebo
17 Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation. Withdrawn NCT02582190 Phase 3 Colchicine group
18 Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy Unknown status NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
19 ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide Unknown status NCT01995799 Phase 2
20 Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis Completed NCT00004482 Phase 2 Cyclosporine;methylprednisolone;Muromonab-CD3;prednisone
21 Myocarditis Treatment Trial Completed NCT00000524 Phase 2 cyclosporine;prednisone
22 Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years) Completed NCT01554943 Phase 2
23 Double Blinded Placebo Controlled Study to Assess Clinical and Antiviral Activity of Valganciclovir (VAL) in Solid Organ Transplant Donors to Reduce Viral Transmission From Donor to Recipient Completed NCT01329185 Phase 2 Valganciclovir;Placebo
24 Safety and Tolerability of Sodium Thiosulfate in Patients Presenting With an Acute Coronary Syndrome Undergoing Coronary Angiography Via Trans-radial Approach: a Dose-escalation Study. Completed NCT03017963 Phase 1, Phase 2 Sodium Thiosulfate Pentahydrate
25 Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial Completed NCT04346446 Phase 2 Convalescent Plasma Transfusion;Random Donor Plasma
26 A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates With Enteroviral Sepsis Syndrome Completed NCT00031512 Phase 2 Placebo;Pleconaril (VP63843)
27 Outcome of Myocardial Inflammation After Steroid Therapy in Thai Systemic Sclerosis Patients: an Open Label Study Recruiting NCT03607071 Phase 2 Prednisolone and taper
28 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation Recruiting NCT03103490 Phase 2 18F-FSPG
29 Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease Recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
30 Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study Recruiting NCT03515304 Phase 2 Evolocumab;Placebo
31 Evolocumab in Patients With ST Elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study Recruiting NCT04082442 Phase 2 Evolocumab;Placebos
32 Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2: Evaluation of Biomarkers of Immunologic and Therapeutic Response Recruiting NCT01884961 Phase 2
33 Groningen Intervention Study for the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction Recruiting NCT02899364 Phase 2 Sodium thiosulfate;Sodium chloride 0.9%
34 ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial Active, not recruiting NCT03004703 Phase 2 Tocilizumab;Sodium chloride 0.9%
35 Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19 Not yet recruiting NCT04380402 Phase 2 Atorvastatin
36 Rapid Recovery of Left Ventricular Function in Patients With Takotsubo Syndrome Undergoing Systemic Infusion of Adenosine: a Randomized Controlled Trial (TITAN Study) Terminated NCT02867878 Phase 2 Adenosine;Saline solution
37 A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients Terminated NCT00311987 Phase 1, Phase 2 3,5-Diiodothyropropionic acid (DITPA) therapy
38 The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity Completed NCT00530101 Phase 1 Doxorubicin
39 Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers Completed NCT01433835 Phase 1 MBX-400
40 Prospective Assessment of the Clinical Utility of Cardiovascular Magnetic Resonance in Patients With Suspected Acute Myocarditis - A Pilot Study for Establishing an International Registry Unknown status NCT01307735
41 Myocardial Inflammation in Systemic Lupus Erythematosus Unknown status NCT01761422
42 2D and Tissue Doppler Imaging Echocardiography Analysis of Left Ventricular Regional Wall Motion and Prognosis Unknown status NCT01092429
43 DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum für Herz- Und Kreislauf-Forschung (DZHK) Unknown status NCT02187263
44 Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases- A New Method to Improve Patient Care Unknown status NCT03199001
45 Monocentric, Prospective, Uncontrolled Pilot Study of Extra Cardiomyocytary Fixation Profile in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography in Patients With Dilated Cardiomyopathy. Unknown status NCT02078141 18F-deoxyglucose (FDG)
46 Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications Unknown status NCT02062008
47 Genetics of Innate Immune Response After Burn Trauma Unknown status NCT00294697
48 Transient ECG Changes in Patients With Acute Biliary Disease Unknown status NCT01706068
49 Effect of Intermittent Normoxic Cardiopulmonary Bypass on Myocardial Reperfusion Injury in Adult Valve Replacement Unknown status NCT01348906
50 Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in ECMO Patients Unknown status NCT01089036

Search NIH Clinical Center for Myocarditis

Sources

Genetic Tests for Myocarditis

About this section
Sources

Anatomical Context for Myocarditis

About this section

MalaCards organs/tissues related to Myocarditis:

40
Heart, T Cells, Endothelial, Brain, Lung, Liver, Monocytes
Sources

Publications for Myocarditis

About this section

Articles related to Myocarditis:

(show top 50) (show all 15609)
# Title Authors PMID Year
1
Cardiac involvement in a female carrier of Duchenne muscular dystrophy. 61 54
18706718 2010
2
IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection. 61 54
19896686 2010
3
Remodeling of dystrophin and sarcomeric Z-band occurs in pediatric cardiomyopathies: a unifying mechanism for force transmission defect. 54 61
19194174 2009
4
Cardiac natriuretic peptides gene expression and secretion in inflammation. 61 54
19158604 2009
5
Activation of STAT1 transcription factor precedes up-regulation of coxsackievirus-adenovirus receptor during viral myocarditis. 61 54
18329552 2008
6
[The expression of coxsackie B virus adenovirus receptor (CAR) in viral myocarditis and dilated cardiomyopathy patients]. 61 54
17896511 2007
7
From oxygen sensing to heart failure: role of thioredoxin. 61 54
17511584 2007
8
Determinants of brain natriuretic peptide gene expression and secretion in acute cardiac allograft rejection. 54 61
17284995 2007
9
[Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice]. 54 61
17254452 2006
10
Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4. 54 61
16949558 2006
11
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. 54 61
17039570 2006
12
Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. 54 61
16806133 2006
13
TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis. 61 54
16631119 2006
14
[The expression of dystrophin in human viral myocarditis and dilated cardiomyopathy]. 61 54
16524176 2006
15
The osteopontin - CD44 pathway is superfluous for the development of autoimmune myocarditis. 61 54
16402410 2006
16
Is diagnostic myocardial biopsy useful in the XXI century? 61 54
15928740 2005
17
Successful treatment of experimental autoimmune myocarditis by adenovirus-mediated gene transfer of antisense CIITA. 61 54
15808836 2005
18
Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. 54 61
15218506 2004
19
Exogenous thioredoxin reduces inflammation in autoimmune myocarditis. 61 54
15353510 2004
20
Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. 61 54
12920582 2004
21
Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat. 61 54
14624362 2004
22
Animal models for autoimmune myocarditis and autoimmune thyroiditis. 61 54
15286386 2004
23
Upregulation of redox-regulating protein, thioredoxin, in endomyocardial biopsy samples of patients with myocarditis and cardiomyopathies. 61 54
12870673 2003
24
Viral causes of cardiac inflammation. 61 54
12826818 2003
25
Analysis of the coxsackievirus B-adenovirus receptor gene in patients with myocarditis or dilated cardiomyopathy. 54 61
12409275 2002
26
Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. 61 54
12018720 2002
27
Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. 54 61
11901182 2002
28
The role of interferon regulatory factors in the cardiac response to viral infection. 54 61
11952139 2002
29
Molecular genetics of left ventricular dysfunction. 54 61
11899244 2001
30
Arrhythmogenic inherited heart muscle diseases in children. 54 61
11781950 2001
31
Interferon regulatory factor 3 is required for viral induction of beta interferon in primary cardiac myocyte cultures. 54 61
10559337 1999
32
Anti-mitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD. 54 61
9528896 1998
33
Cardiac troponin T in patients with clinically suspected myocarditis. 54 61
9350939 1997
34
iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. 61 54
9244230 1997
35
Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. 54 61
8978317 1997
36
Venticular expression of atrial and brain natriuretic peptides in patients with myocarditis. 54 61
8789180 1995
37
Role of nitric oxide in the regulation of myocardial function. 61 54
7568904 1995
38
A case of creatine kinase isomer anomaly in relation to the diagnosis of acute myocardial infarction. 54 61
8051787 1994
39
[Autoantibodies against the beta 1-adrenergic receptor in myocarditis and dilated cardiomyopathy: localization of two epitopes]. 61 54
1283934 1992
40
[The significance of myoglobin determination in the differential diagnosis of chest pain syndrome]. 61 54
2053302 1991
41
Relation between myoglobin and cardiac dysfunction in myocarditis--immunohistochemical study of endomyocardial biopsy specimens. 54 61
2010944 1991
42
Shenmai injection suppresses multidrug resistance in MCF-7/ADR cells through the MAPK/NF-κB signalling pathway. 61
32251615 2020
43
Liver-Specific siRNA-Mediated Stat3 or C3 Knockdown Improves the Outcome of Experimental Autoimmune Myocarditis. 61
32577433 2020
44
Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. 61
32402518 2020
45
Neonatal acute liver failure due to enteroviruses: a 14 years single NICU experience. 61
30513031 2020
46
Early cardiac magnetic resonance imaging in troponin-positive acute chest pain and non-obstructed coronary arteries. 61
32447308 2020
47
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction. 61
31754904 2020
48
Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. 61
32291207 2020
49
Cardiovascular magnetic resonance clarifies arrhythmogenicity in asymptomatic young athletes with ventricular arrhythmias undergoing pre-participation evaluation. 61
32537014 2020
50
Myocardial injury and COVID-19: Possible mechanisms. 61
32360126 2020
Sources

Variations for Myocarditis

About this section

ClinVar genetic disease variations for Myocarditis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCD1 NM_000033.4(ABCD1):c.1866-1G>CSNV Likely pathogenic 523312 rs1557055311 X:153008674-153008674 X:153743220-153743220
2 AMER1 NM_152424.4(AMER1):c.1907_1908GA[2] (p.Glu637fs)short repeat Uncertain significance 523561 rs1555933313 X:63411255-63411256 X:64191375-64191376
Sources

Expression for Myocarditis

About this section
Search GEO for disease gene expression data for Myocarditis.
Sources

Pathways for Myocarditis

About this section

Pathways related to Myocarditis according to KEGG:

36
# Name Kegg Source Accession
1 Viral myocarditis hsa05416

Pathways related to Myocarditis according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.96 TNF NOS2 ITGB2 IL6 ICAM1 HLA-DQB1
2
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.41 ITGB2 ICAM1 HLA-DQB1 HLA-B CXADR CD86
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.29 TNF NOS2 ITGB2 IL6 ICAM1 HLA-DQB1
4
Measles 36
Show member pathways
 12.78 TNF IL6 ICAM1 HLA-DQB1 HLA-B CD40
5
Immune response NFAT in immune response 22
Show member pathways
 12.59 TNF HLA-DQB1 CD86 CD40LG CD40
6
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.35 HLA-DQB1 CD86 CD40LG CD40
7
Immune response CCR3 signaling in eosinophils 22
Show member pathways
 12.3 NOS2 MYH6 ITGB2 ICAM1
8
Toxoplasmosis 36
Show member pathways
 12.21 TNF NOS2 ITGB2 HLA-DQB1 CD40LG CD40
9
Human T-cell leukemia virus 1 infection 36
12.21 TNF ITGB2 IL6 ICAM1 HLA-DQB1 HLA-B
10
Allograft rejection 1 36
Show member pathways
 12.21 TNF MYH6 ITGB2 IL6 ICAM1 HLA-DQB1
11
Tuberculosis 36
12.19 TNF NOS2 ITGB2 IL6 HLA-DQB1
12
Dilated cardiomyopathy (DCM) 36
Show member pathways
 12.18 TNNI3 TNF MYH6 IL6 DMD DAG1
13
Adhesion 4
12 ITGB2 ICAM1 DSP CXADR
14
Spinal Cord Injury 1
11.98 TNF NOS2 IL6 ICAM1
15
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
11.98 ITGB2 ICAM1 HLA-B CXADR CD40LG CD40
16
Interleukin-4 and 13 signaling 65
11.95 TNF NOS2 ITGB2 IL6 ICAM1
17
NF-kappa B signaling pathway 36
11.9 TNF ICAM1 CD40LG CD40
18
Amoebiasis 36
11.89 TNF NOS2 ITGB2 IL6
19
Cell adhesion molecules (CAMs) 36
11.87 ITGB2 ICAM1 HLA-DQB1 HLA-B CD86 CD40LG
20
Hematopoietic cell lineage 36
11.86 TNF IL6 HLA-DQB1 CD55
21
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.76 TNF CD40LG CD40
22
Pertussis 36
11.73 TNF NOS2 ITGB2 IL6
23
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.7 TNF CD40LG CD40
24
Rheumatoid arthritis 36
11.7 TNF ITGB2 IL6 ICAM1 HLA-DQB1 CD86
25
Striated Muscle Contraction 65 1
11.69 TNNI3 MYH6 DMD
26
Lung fibrosis 1
11.62 TNF IL6 DSP
27
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.6 TNF NOS2 IL6 ICAM1 CD40LG
28
Legionellosis 36
11.57 TNF ITGB2 IL6
29
Interleukin-10 signaling 65
11.52 TNF IL6 ICAM1 CD86
30
MSP-RON Signaling 63
11.49 TNF NOS2 ITGB2
31
amb2 Integrin signaling 1
11.49 TNF ITGB2 IL6 ICAM1
32
Type II interferon signaling (IFNG) 1
11.37 NOS2 ICAM1 HLA-B
33
African trypanosomiasis 36
11.36 TNF IL6 ICAM1
34
Inflammatory Response Pathway 1
11.31 CD86 CD40LG CD40
35
Malaria 36
11.13 TNF ITGB2 IL6 ICAM1 CD40LG CD40
36
Effects of Nitric Oxide 1
10.55 NOS2 MB
Sources

GO Terms for Myocarditis

About this section

Cellular components related to Myocarditis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.17 TNF NOS2 ITGB2 ICAM1 HLA-DQB1 HLA-B
2 extracellular exosome GO:0070062 10.06 MB ITGB2 ICAM1 HLA-B DSP DAG1
3 cell GO:0005623 9.86 TNNI3 NOS2 IL6 ICAM1 DMD DAG1
4 external side of plasma membrane GO:0009897 9.7 TNF ITGB2 ICAM1 DAG1 CD86 CD40LG
5 filopodium GO:0030175 9.63 DMD DAG1 CXADR
6 ficolin-1-rich granule membrane GO:0101003 9.61 ITGB2 DSP CD55
7 cell surface GO:0009986 9.61 TNF ITGB2 ICAM1 HLA-B DMD CD86
8 myofibril GO:0030016 9.54 TNNI3 MYH6 DMD
9 membrane raft GO:0045121 9.17 TNF ITGB2 ICAM1 DMD DAG1 CXADR

Biological processes related to Myocarditis according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.97 ICAM1 HLA-B DAG1 CXADR CD86 CD55
2 extracellular matrix organization GO:0030198 9.93 TNF ITGB2 ICAM1 DAG1
3 immune response GO:0006955 9.93 TNF IL6 HLA-DQB1 HLA-B CD86 CD40LG
4 inflammatory response GO:0006954 9.91 TNF NOS2 ITGB2 IL6 CD40LG CD40
5 leukocyte migration GO:0050900 9.88 TNF ITGB2 ICAM1 CXADR
6 cytokine-mediated signaling pathway GO:0019221 9.88 TNF NOS2 ITGB2 IL6 ICAM1 CD86
7 cell-cell adhesion GO:0098609 9.86 ITGB2 ICAM1 DSP CXADR
8 regulation of immune response GO:0050776 9.85 ITGB2 ICAM1 HLA-B CXADR CD40LG CD40
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL6 CD40
10 interferon-gamma-mediated signaling pathway GO:0060333 9.77 ICAM1 HLA-DQB1 HLA-B
11 positive regulation of T cell proliferation GO:0042102 9.76 IL6 CD86 CD40LG
12 cardiac muscle contraction GO:0060048 9.71 TNNI3 MYH6 DMD
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 TNF ITGB2 ICAM1
14 muscle filament sliding GO:0030049 9.69 TNNI3 MYH6 DMD
15 leukocyte cell-cell adhesion GO:0007159 9.65 ITGB2 ICAM1 CD40LG
16 viral entry into host cell GO:0046718 9.65 ICAM1 DAG1 CXADR CD86 CD55
17 cellular response to lipopolysaccharide GO:0071222 9.63 TNF NOS2 IL6 ICAM1 CD86 CD40
18 positive regulation of neuroinflammatory response GO:0150078 9.62 TNF IL6
19 cardiac muscle fiber development GO:0048739 9.62 MYH6 CXADR
20 response to denervation involved in regulation of muscle adaptation GO:0014894 9.61 DMD DAG1
21 negative regulation of lipid storage GO:0010888 9.61 TNF IL6
22 CD40 signaling pathway GO:0023035 9.57 CD40LG CD40
23 cellular extravasation GO:0045123 9.55 TNF ITGB2
24 regulation of immunoglobulin secretion GO:0051023 9.5 TNF CD40LG CD40
25 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.43 TNF ITGB2 IL6 ICAM1 CD40LG CD40
26 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 8.92 TNF ITGB2 IL6 ICAM1

Molecular functions related to Myocarditis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TNNI3 TNF NPPB NOS2 MYH6 ITGB2
2 signaling receptor activity GO:0038023 9.67 ITGB2 ICAM1 CD86 CD40
3 cell adhesion molecule binding GO:0050839 9.43 ITGB2 DSP CXADR
4 vinculin binding GO:0017166 9.4 DMD DAG1
5 integrin binding GO:0005178 9.35 ITGB2 ICAM1 DMD CXADR CD40LG
6 dystroglycan binding GO:0002162 9.32 DMD DAG1
7 virus receptor activity GO:0001618 9.02 ICAM1 DAG1 CXADR CD86 CD55
Sources

Sources for Myocarditis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....